At the same time, VEGF correlated with the presence of hypo-complementemia, a serological sign in pSS of ongoing inflammation and systemic expression and predictor of the adverse outcomes (lymphoma development and death), which also supports the role of VEGF as disease activity marker in pSS. Here, VEGFA is linked to peeling skin syndrome.